- Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib studyHu, Yue; Li, Hai Jun; Zhang, Hong; Chen, Jinjun; Xu, Zhongyuan; You, Hong; Dong, Ruihua; Zhu, Xiaoxue; Chen, Hong; Peng, Yun; Li, Jing; Li, Xiaojiao; Zhang, Lei; Cao, Di; Jin, He; Qiu, Dongdong; Yang, Aruhan; Liu, Jingrui; Jia, Haiyan; Lou, Jinfeng; Niu, Junqi; Ding, Yanhua被引 1
- NOVEL, FIRST-IN-CLASS, FATTY ACID SYNTHASE (FASN) INHIBITOR TVB-2640 DEMONSTRATES ROBUST CLINICAL EFFICACY AND SAFETY IN A GLOBAL PHASE 2 RANDOMIZED PLACEBO-CONTROLLED NASH TRIAL (FASCINATE-1) CONDUCTED IN THE US AND CHINALoomba, Rohit; Rinella, Mary E.; Harrison, Stephen A.; Wong, Vincent; Ratziu, Vlad; Gores, Gregory J.; Neuschwander-Tetri, Brent A.; Mohseni, Rizwana; Lucas, Kathryn Jean; Gutierrez, Julio A.; Perry, Robert; Rahimi, Robert S.; Trotter, James F.; Deng, Hong; Xie, Qing; Zhang, Jing; Wu, Lixian; You, Hong; Zhong, Bihui; Hou, JinLin; Yang, Yongfeng; Lu, Yan; He, Handan; Palmer, Melissa; Wu, Jinzi; Grimmer, Katharine; McCulloch, William; O'Farrell, Marie; Martins, Eduardo B.; Kemble, George72nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, ELECTR NETWORK, 2021-11-12 To 2021-11-15.
- HEC96719, a novel tricyclic farnesoid X receptor agonist for treatment of non-alcoholic steatohepatitis: results of preclinical study and phase I trialCao, Shengtian; Yang, Xinye; Dai, Liting; Li, Jing; Zhang, Ying Jun; Wang, Xiaojun; Wang, Yan
会议论文
SAFETY, PHARMACOKINETICS AND EFFICACY OF THE NOVEL PAN-PHOSPHODIESTERASE INHIBITOR ZSP1601 IN 36 NASH PATIENTS: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTIPLE-DOSE ESCALATION PHASE IB STUDY INTERIM ANALYSIS
4阅读
